Semantic Scholar
Open Access
2012
5188 sitasi
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
R. Rosell
E. Carcereny
R. Gervais
A. Vergnenègre
B. Massutí
+52 lainnya
Topik & Kata Kunci
Penulis (57)
R
R. Rosell
E
E. Carcereny
R
R. Gervais
A
A. Vergnenègre
B
B. Massutí
E
E. Felip
R
R. Palmero
R
R. García-Gómez
C
C. Pallarés
J
J. Sánchez
R
R. Porta
M
M. Cobo
P
P. Garrido
F
F. Longo
T
T. Morán
A
A. Insa
F
F. de Marinis
R
R. Corre
I
I. Bover
A
A. Illiano
É
É. Dansin
J
J. de Castro
M
M. Milella
N
N. Reguart
G
G. Altavilla
U
U. Jiménez
M
M. Provencio
M
M. Moreno
J
J. Terrasa
J
J. Muñoz-Langa
J
J. Valdivia
D
D. Isla
M
M. Dómine
O
O. Molinier
J
J. Mazières
N
N. Baize
R
R. García-Campelo
G
G. Robinet
D
D. Rodríguez-Abreu
G
G. López-Vivanco
V
V. Gebbia
L
Lioba Ferrera-Delgado
P
P. Bombaron
R
R. Bernabé
A
A. Bearz
Á
Á. Artal
E
E. Cortesi
C
C. Rolfo
M
M. Sánchez-Ronco
A
A. Drozdowskyj
C
C. Queralt
I
I. de Aguirre
J
J. Ramírez
J
J. Sánchez
M
M. Molina
M
M. Taron
L
L. Paz-Ares
Format Sitasi
Rosell, R., Carcereny, E., Gervais, R., Vergnenègre, A., Massutí, B., Felip, E. et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.. https://doi.org/10.1016/S1470-2045(11)70393-X
Akses Cepat
PDF tidak tersedia langsung
Cek di sumber asli →Informasi Jurnal
- Tahun Terbit
- 2012
- Bahasa
- en
- Total Sitasi
- 5188×
- Sumber Database
- Semantic Scholar
- DOI
- 10.1016/S1470-2045(11)70393-X
- Akses
- Open Access ✓